Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

(Neutral)

Key Terms

spinal muscular atrophy medical

A genetic condition in which the “wiring” between the spinal cord and muscles fails, causing progressive loss of muscle strength and motor skills from infancy through adulthood as the nerve cells that move muscles deteriorate. Investors pay attention because the condition creates a clear, long-term need for specialized therapies, diagnostics and ongoing care — meaning successful drugs or tests can attract premium pricing, sustained demand and significant regulatory and reimbursement scrutiny that materially affect biotech and healthcare valuations.

myostatin biology medical

Myostatin biology is the study of the protein myostatin and the signals it uses to limit muscle growth and control repair. For investors, it matters because drugs or therapies that block or alter myostatin act like releasing a brake on muscle development—offering potential treatments for muscle-wasting diseases, age-related decline or injury recovery—so clinical results, safety and regulatory decisions in this area can strongly affect a company’s value.

monoclonal antibodies medical

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

neuromuscular diseases medical

Neuromuscular diseases are a group of medical conditions that damage the nerves controlling muscles or the muscles themselves, causing weakness, poor coordination, or loss of movement—think of it as problems with the wiring or motors that make the body move. They matter to investors because they often involve clear unmet medical needs, long-term care or durable treatments, and focused patient populations, which can drive drug development, pricing power, and regulatory attention in the healthcare market.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/29/2026 - 08:00 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46^th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for approximately 90 days.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock^® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.